DE60239220D1 - ClC-2-KANALÖFFNER ZUR BEHANDLUNG VON MAGEN- ODER DARM-ULCUS - Google Patents
ClC-2-KANALÖFFNER ZUR BEHANDLUNG VON MAGEN- ODER DARM-ULCUSInfo
- Publication number
- DE60239220D1 DE60239220D1 DE60239220T DE60239220T DE60239220D1 DE 60239220 D1 DE60239220 D1 DE 60239220D1 DE 60239220 T DE60239220 T DE 60239220T DE 60239220 T DE60239220 T DE 60239220T DE 60239220 D1 DE60239220 D1 DE 60239220D1
- Authority
- DE
- Germany
- Prior art keywords
- darm
- ulcus
- clc
- stomach
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102100023509 Chloride channel protein 2 Human genes 0.000 title 1
- 101710091667 Chloride channel protein 2 Proteins 0.000 title 1
- 210000002784 stomach Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33154201P | 2001-11-19 | 2001-11-19 | |
PCT/JP2002/012037 WO2003043639A2 (en) | 2001-11-19 | 2002-11-19 | PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60239220D1 true DE60239220D1 (de) | 2011-03-31 |
Family
ID=23294388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60239220T Expired - Lifetime DE60239220D1 (de) | 2001-11-19 | 2002-11-19 | ClC-2-KANALÖFFNER ZUR BEHANDLUNG VON MAGEN- ODER DARM-ULCUS |
Country Status (12)
Country | Link |
---|---|
US (2) | US7732487B2 (de) |
EP (2) | EP1455794B1 (de) |
JP (1) | JP4377692B2 (de) |
AR (1) | AR037556A1 (de) |
AT (1) | ATE498402T1 (de) |
AU (1) | AU2002348670A1 (de) |
CA (1) | CA2466906C (de) |
DE (1) | DE60239220D1 (de) |
DK (1) | DK1455794T3 (de) |
ES (1) | ES2359804T3 (de) |
TW (1) | TWI263505B (de) |
WO (1) | WO2003043639A2 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR037524A1 (es) | 2001-11-14 | 2004-11-17 | Sucampo Ag | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion |
ES2379652T3 (es) * | 2002-10-23 | 2012-04-30 | Sucampo Ag | Compuestos de prostaglandina para el tratamiento de obesidad |
KR101164838B1 (ko) * | 2002-12-27 | 2012-07-11 | 수캄포 아게 | 복부 불쾌감 치료용 프로스타글랜딘의 유도체 |
EP1641462B1 (de) | 2003-07-03 | 2010-11-24 | Sucampo AG | Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner |
TWI387454B (zh) | 2004-09-02 | 2013-03-01 | Sucampo Ag | 治療胃腸道疾病之方法及組成物 |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
JP5241484B2 (ja) | 2005-03-07 | 2013-07-17 | ザ ユニヴァーシティー オヴ シカゴ | 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用 |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
RU2468800C2 (ru) * | 2005-04-12 | 2012-12-10 | Сукампо Аг | Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний |
PT1884234E (pt) | 2005-05-17 | 2012-07-26 | Santen Pharmaceutical Co Ltd | Agente profiláctico ou terapêutico para distúrbio corneano e conjuntival |
JP2010519177A (ja) * | 2007-02-27 | 2010-06-03 | スキャンポ・アーゲー | ミトコンドリアを保護するための組成物および方法 |
RU2460526C2 (ru) * | 2007-05-25 | 2012-09-10 | Сантен Фармасьютикал Ко., Лтд. | Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна |
US20090030072A1 (en) | 2007-07-03 | 2009-01-29 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
US20090012165A1 (en) | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
JP2017052723A (ja) * | 2015-09-10 | 2017-03-16 | 株式会社Lttバイオファーマ | ドライアイ改善剤 |
JP6710040B2 (ja) * | 2015-11-06 | 2020-06-17 | 江崎グリコ株式会社 | 唾液分泌促進剤及び口腔用組成物 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225439A (en) | 1987-01-28 | 1993-07-06 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
CA1323364C (en) | 1987-01-28 | 1993-10-19 | Ryuzo Ueno | Prostaglandins e and anti ulcer agents containing same |
US5380709A (en) | 1987-01-28 | 1995-01-10 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti ulcers containing same |
US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
EP0310305B1 (de) * | 1987-10-02 | 1992-07-22 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Kathartica |
US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | 16,16−ジフルオロ−15−オキソ−15−デオキシpge誘導体 |
CA2027814C (en) | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
CA2030345C (en) | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
US5254588A (en) | 1989-11-22 | 1993-10-19 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo | Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds |
CA2030346C (en) | 1989-11-22 | 2000-04-11 | Ryuji Ueno | Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds |
US5256696A (en) | 1989-11-22 | 1993-10-26 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo | Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds |
CA2030344C (en) | 1989-11-22 | 2000-04-18 | Ryuji Ueno | Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds |
CA2041417C (en) | 1990-05-01 | 2002-05-21 | Ryuji Ueno | Treatment of pancreatic disease with 15-keto-prostaglandin compounds |
US5100647A (en) | 1990-10-02 | 1992-03-31 | The Trustees Of The University Of Pennsylvania | Method and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas, and for diuretic treatment |
CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
US6015828A (en) | 1996-05-31 | 2000-01-18 | Cuppoletti; John | Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases |
AU739343B2 (en) | 1997-11-28 | 2001-10-11 | Sucampo Ag | Endothelin antagonist |
TWI225398B (en) | 1999-07-14 | 2004-12-21 | R Tech Ueno Ltd | Composition for treatment of external secretion disorders |
BR0016021A (pt) * | 1999-12-22 | 2003-07-15 | Inspire Pharmaceuticals Inc | Processo de tratamento de doenças do trato gastrointestinal com agonistas do receptor purinérgico |
AU4472701A (en) | 2000-04-06 | 2001-10-23 | Sucampo Ag | Bile secretion promoting composition |
US6414016B1 (en) | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
TWI302100B (en) | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
MXPA04002006A (es) | 2001-08-31 | 2004-06-07 | Sucampo Ag | Analogos de prostagladina como abridor del canal de cloruro. |
-
2002
- 2002-11-18 TW TW91133604A patent/TWI263505B/zh not_active IP Right Cessation
- 2002-11-18 US US10/298,062 patent/US7732487B2/en not_active Expired - Fee Related
- 2002-11-19 EP EP20020781814 patent/EP1455794B1/de not_active Expired - Lifetime
- 2002-11-19 CA CA 2466906 patent/CA2466906C/en not_active Expired - Fee Related
- 2002-11-19 AR ARP020104435 patent/AR037556A1/es not_active Application Discontinuation
- 2002-11-19 ES ES02781814T patent/ES2359804T3/es not_active Expired - Lifetime
- 2002-11-19 DK DK02781814T patent/DK1455794T3/da active
- 2002-11-19 DE DE60239220T patent/DE60239220D1/de not_active Expired - Lifetime
- 2002-11-19 JP JP2003545320A patent/JP4377692B2/ja not_active Expired - Fee Related
- 2002-11-19 AU AU2002348670A patent/AU2002348670A1/en not_active Abandoned
- 2002-11-19 AT AT02781814T patent/ATE498402T1/de active
- 2002-11-19 EP EP10010108A patent/EP2364708A3/de not_active Withdrawn
- 2002-11-19 WO PCT/JP2002/012037 patent/WO2003043639A2/en active Application Filing
-
2010
- 2010-04-16 US US12/761,979 patent/US20100204332A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2359804T3 (es) | 2011-05-27 |
JP4377692B2 (ja) | 2009-12-02 |
US20100204332A1 (en) | 2010-08-12 |
TW200304829A (en) | 2003-10-16 |
EP2364708A2 (de) | 2011-09-14 |
EP1455794A2 (de) | 2004-09-15 |
DK1455794T3 (da) | 2011-03-14 |
JP2005515186A (ja) | 2005-05-26 |
EP1455794B1 (de) | 2011-02-16 |
AU2002348670A1 (en) | 2003-06-10 |
US7732487B2 (en) | 2010-06-08 |
EP2364708A3 (de) | 2011-12-28 |
CA2466906A1 (en) | 2003-05-30 |
TWI263505B (en) | 2006-10-11 |
WO2003043639A2 (en) | 2003-05-30 |
ATE498402T1 (de) | 2011-03-15 |
CA2466906C (en) | 2011-10-18 |
US20030166632A1 (en) | 2003-09-04 |
AR037556A1 (es) | 2004-11-17 |
WO2003043639A3 (en) | 2004-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60239220D1 (de) | ClC-2-KANALÖFFNER ZUR BEHANDLUNG VON MAGEN- ODER DARM-ULCUS | |
DE60234760D1 (de) | Phenylindole zur behandlung von hiv | |
ATE293610T1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
NO20035609L (no) | Fremgangsmate for kontinuerlig naftabehandling | |
ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
ATE556059T1 (de) | Pyrazolderivate zur behandlung von hiv | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
DE60115874D1 (de) | Instrument zur chirurgischen behandlung | |
NO20035156D0 (no) | Fremgangsmåter for brönnbehandling | |
ATE293447T1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
ATE265860T1 (de) | Impstoff zur behandlung von atherosclerosis | |
DE60019158D1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
ATE384522T1 (de) | Medikamente zur chemotherapeutischen behandlung von erkrankungen | |
DE60123238D1 (de) | Zusammensetzungen zur behandlung von autoimmunkrankheiten | |
DE60218451D1 (de) | 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation | |
DE60229959D1 (de) | Kombinationstherapie zur behandlung von krebs | |
DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
DE60233186D1 (de) | Verbessertes System zur Behandlung von Elementarschwefel-Rückständen | |
ATE313540T1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
ATE279386T1 (de) | Retinoide zur behandlung von emphysem | |
DE60236743D1 (de) | Zur behandlung androgenabhängiger krankheiten | |
NO20034123L (no) | Fremgangsmåte for behandling av brennstoff | |
DE60214355D1 (de) | Exemestan zur behandlung von hormonabhängigen störungen | |
DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis |